Research Article

Cardioprotection of immature heart by simultaneous activation of PKA and EPAC: a role for the Mitochondrial Permeability Transition Pore

M Lewis 1*, I Khaliulin2, K Hall3, and M.S. Suleiman3

1School of Physiology, Pharmacology & Neuroscience, University of Bristol, Bristol BS8 1TD, UK
2School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel
3Bristol Medical School, University of Bristol, Bristol BS8 1TH, UK
* Correspondence: martin.lewis@bris.ac.uk

Abstract: Metabolic and ionic changes during ischaemia predispose the heart to the damaging effects of reperfusion. Such changes and the resulting injury differ between immature and adult heart. Therefore, cardioprotective strategies for adults need to be tested in immature heart. We have recently shown that simultaneous activation of PKA and EPAC confers marked cardioprotection in adult hearts. The aim of this study is to investigate the efficacy of this intervention in immature hearts and determine whether the mitochondrial permeability transition pore (MPTP) is involved.

Isolated perfused Langendorff hearts from both adult and immature rats were exposed to global ischaemia and reperfusion injury (I/R) following control perfusion or perfusion after an equilibration period with activators of PKA and/or EPAC. Functional outcome and reperfusion injury were measured and in parallel, mitochondria were isolated following 5 min reperfusion to determine whether cardioprotective interventions involved changes in MPTP opening behaviour. Perfusion for 5 minutes preceding ischaemia of injury-matched adult and immature hearts with 5 µM 8-Br (8-Br-cAMP-AM), an activator of both PKA and EPAC, led to significant reduction in post-reperfusion CK release and infarct size. Perfusion with this agent also led to a reduction in MPTP opening propensity in both adult and immature hearts. These data show that immature hearts are innately more resistant to I/R injury than adults, and that this is due to a reduced tendency to MPTP opening following reperfusion. Further, simultaneous stimulation of PKA & EPAC causes cardioprotection which is additive to the innate resistance.

Keywords: Ischaemia/reperfusion Injury, development, mitochondria, immature heart

1. Introduction

Cardiac ischaemia/reperfusion (I/R) injury occurs during cardiac surgery [1], and is unavoidable due to the use of cardiac isolation through aortic cross-clamping and cessation of coronary blood flow. It is a major contributor to the morbidity and mortality [2]. The MPTP is primed by the accumulation of Ca²⁺ and reactive oxygen species (ROS) during index ischaemia. However, it remains closed over the period of ischaemia because of acidosis. A further burst of ROS [3, 4] and subsequent Ca²⁺ overload [5] trigger the opening of this pore at the commencement of reperfusion.

In our previous work, and that of others, we have shown that the cAMP signal transduction pathways are critical for the mediation of pharmacologically induced cardioprotective effects similar to those seen with ischaemic and temperature preconditioning [6-8]. Traditional approaches targeting the cAMP signaling pathways have encountered the problem that this approach has relied on β-adrenergic receptors (βAR) stimulation which may be impaired in heart failure [9, 10]. Therefore, cardioprotection by activating
cAMP-related signaling mechanisms bypassing the adrenoreceptors would give a significant therapeutic advantage in those situations where protection is most needed. Conventionally, the biological effects of cAMP in the heart are ascribed to PKA activity [11]. However, it has become clear that cAMP also activates Epac (a guanine nucleotide exchange protein directly activated by cAMP) [12]. The cAMP/Epac pathway exists independently of and in parallel to the cAMP/PKA signaling pathway [13, 14]. Therefore, the use of newly available cAMP analogues that can act selectively on either PKA or Epac, or both simultaneously, represents a valuable tool to identify the involvement and the relative contribution of these cAMP sensors in cardioprotection [15]. We have recently shown that simultaneous activation of PKA and Epac using cAMP permeable analogues provided a strong cardioprotection against I/R injury in adult hearts [16, 17].

However, adult hearts are known to be more vulnerable to I/R injury compared to immature hearts in animal models across a range of stages of post-natal development [18, 19]. The underlying mechanisms are not fully understood but the effect of calcium mobilisation upon the MPTP have been implicated amongst the wide range of anatomical and physiological changes over the course of post-natal development [16, 20-22]. Whether or not these protective mechanisms are effective in the immature heart is unclear. However, it is of therapeutic importance given that a large and increasing number of children each year often undergo repeated surgery for congenital heart defects. Thus, an understanding of how the young heart differs from the mature one is required in order to develop strategies for myocardial protection during surgery.

In this study, we investigated the cardioprotective efficacy of cAMP/PKA and cAMP/Epac signaling pathways in ex vivo perfused adult and 14-day postnatal heart exposed to global ischaemia/reperfusion. We used cell permeable cAMP analogues (described in Table 1) that are selective activators of either PKA or Epac, or both. Measurements of biochemical and histological indications of myocardial injury were made. Alterations in MPTP opening behaviour in both age groups following I/R were then investigated.

2. Results
2.1 The effects of cAMP analogue results in whole heart
2.1.1 Effects of the cAMP analogues on CK Activity in Coronary Effluent
Perfused adult hearts, in Figure 1, show that CK release occurs rapidly at the beginning of reperfusion in the control group, peaking in the 5-min fraction. This is in contrast to the activity from those hearts perfused with either 8-Br, 6-Bnz or CPT prior to ischaemia. All of those groups had a delayed peak, and a reduced total release vs. control. CPT and 6-Bnz had an indistinguishable effect from one another, but 8-Br produced the greatest reduction in CK release at all time points and in cumulative activity over the 30-min period studied.
Hearts from 14-day old rats were exposed to 30- (Error! Reference source not found.) and 50- (Error! Reference source not found.) min of global ischaemia. Those immature hearts exposed to 30 min of ischaemia did not show any difference between the control and any of the intervention groups at any of the time points studied. The peak activity level in the control was reduced significantly, to 58.6% of that seen in the adult control.

Figure 1 Activity of creatine kinase in coronary effluent from adult hearts in perfusion experiments. Normalised to coronary flow rate. Error bars represent Mean ±SE. n=6 per group.

Figure 2 Activity of creatine kinase in coronary effluent from P14 hearts in perfusion experiments exposed to 30 min of global ischaemia. Normalised to coronary flow rate. Error bars represent Mean ±SE. n=6 per group.
group, and arrived in a later fraction. Similarly, the area under the activity time curve in the P14 group was 57.1% of that in the adult representing a significantly lower overall degree of injury.

Exposure of 14-day old hearts to 50 min of ischaemia was performed in order to attempt to match the degree of injury between the age groups. The total area under this curve was 97.1% that of the adult hearts; so a comparable degree of injury was achieved. In this group, there was a marked reduction in CK activity in the coronary effluent in those hearts exposed to any of the cAMP analogues prior to ischaemia (Figure 3, Error!)

![Figure 3](image-url)  
*Figure 3 Activity of creatine kinase in coronary effluent from P14 hearts in perfusion experiments exposed to 50 min of global ischaemia. Normalised to coronary flow rate. Error bars represent Mean ±SE. n=6 per group.*

![Figure 4](image-url)  
*Figure 4 Total activity for CK in each age and treatment group for the cAMP analogue experiments. Total activity taken as estimated area under activity-time curves summed by trapezoidal addition of mean values for each time point. Bars represent mean AUC ± SE; * = p<0.05 vs same age group control. N=6 per group.*
Reference source not found.). This was most marked with 8-Br, and also seen with 6-Bnz. CPT did not significantly reduce the CK activity.

2.1.2 Effects of the cAMP analogues on infarct size following perfusion

A similar pattern was seen in infarct size measured following perfusion (Error! Reference source not found.). In adult hearts, a 30-min ischaemic injury in the control group produced a mean infarct area of 56.8%. For the drug-treated hearts, perfusion with 8-Br, the non-selective cAMP analogue, produced a marked and significant reduction of the infarcted area, to a mean of 24.8% representing an infarct 43.7% the size in the control group. Neither perfusion with 6-Bnz (an activator of PKA) nor CPT (an EPAC activator) were associated with a significant reduction in infarct size in the adult hearts.

The group of P14 hearts subjected to an ischaemic injury of 30 min in length, showed an average infarct size of 34.75%. None of the cAMP analogues in this group produced a statistically significant reduction in the area infarcted.

However, when the ischaemic time was increased to 50 min, the infarcted area increased to 55.6%, comparable to the adult hearts given a 30 min cessation of perfusion. In this group, the addition of 8-Br prior to ischaemia did produce a significant reduction in the infarct size to 26.4%. Again, perfusion with 6-Bnz or CPT did not meaningfully reduce the infarct size; so in no group perfused with either of these agents was the magnitude in reduction of the infarct size sufficient to reach statistical significance.

Figure 5 Cross sectional proportionate infarct size vs age group & cAMP analogue used to perfuse prior to I/R injury. Mean ±SE; * p<0.05 vs. same age group control. 2 separate P14 groups were used with different ischaemic durations- see text. N=6 per group.
2.2 Mitochondrial permeability transition pore inhibition

The effect of Isoprenaline induced Cardiac β-Adrenoreceptor Stimulation on MPTP Opening in Adult and Immature Hearts not exposed to I/R Injury

Mitochondria from similarly perfused hearts were examined in order to assess their sensitivity to swelling in response to exogenous calcium. The first group were perfused with control perfusate or perfusate & isoprenaline and no ischaemia in order to demonstrate a physiological response.

In both adult and P14 hearts isoprenaline perfusion caused a significant reduction in mitochondrial swelling; this was true for both absolute magnitude of mitochondrial swelling (Error! Reference source not found., Error! Reference source not found.; adults 26 %, P14 33%) or maximal rate of change of absorbance (data not shown; adults 59%, P14 40%).

![Effect of Isoprenaline on Amplitude of Ca\(^{2+}\)-induced Mitochondrial Swelling- Adult](image)

Figure 6 Change in absorbance following addition of calcium to mitochondrial suspension with or without perfusion with isoprenaline. Orange- change in OD at baseline; blue- change in OD after calcium addition.

* = p<0.05; data expressed as mean value; error bars= standard error of the mean. N=6 per group
2.2.1 Amelioration of the effect of I/R injury on MPTP opening by Isoprenaline or 8-Br-cAMP perfusion

Figure shows the effect of ischaemia and reperfusion injury on MPTP opening propensity. This Figure demonstrates that in both Adult- and P14-derived mitochondria a significant increase in MPTP opening was observed following I/R compared to control. Experiments involving perfusion with the cAMP analogues, isoprenaline, or none of the agents (control were performed. Then, I/R was produced followed by mitochondrial isolation. These results are also presented in Figure. Isoprenaline perfusion caused a significant reduction in MPTP opening in adult hearts to below the level seen in hearts not receiving I/R injury. This pattern, albeit at a lower magnitude, was also seen in the equivalent experiments on P14 hearts. A significant reduction in amplitude of swelling was seen following perfusion with isoprenaline, to a level comparable to the non-I/R control.

Perfusion with 8-Br, the non-selective agonist of both PKA and EPAC, reduced MPTP sensitivity in adult and P14 hearts. This was indistinguishable from the uninjured control in adults. In the P14 group, there was also a significant reduction in the amplitude of swelling, although it was not reduced to the level of hearts not exposed to an I/R injury.

2.2.2 Effects of CPT & 6-Bnz

The effects of the two selective cAMP analogues are also shown in Figure. In both the adult and P14 groups, neither agent produced a significant reduction in absolute magnitude of mitochondrial swelling. However, in the P14 hearts, both CPT and 6-Bnz produced significant reductions in the rate of swelling vs the I/R control (6 Bnz, -7.6±1.0

Figure 7 Change in absorbance in P14 extract following addition of calcium to mitochondrial suspension with and without isoprenaline perfusion. Orange- change in OD at baseline; blue- change in OD after calcium addition. *= p<0.05; data represented as mean; error bars= standard error of the mean. (n=6 per group)
x 10^-4 OD/s p<0.005, CPT, -8.1±0.9 x 10^-4 OD/s, p<0.005) although these remained notably greater than the non-I/R control (5.1±1.4 x 10^-5 OD/s). In the adult hearts, whilst both CPT and 6-Bnz produced observable reductions in swelling rate, only 6-Bnz reached significance; 1.2±0.4 x 10^-3 OD/s, p = 0.041.

Figure 8 Summary of effects of interventions targeting different stages of the β adrenergic signalling pathway prior to IR on magnitude of change in optical density of mitochondria. Error bars = 1 SEM. *P<0.05, vs IR group in corresponding age group. #P<0.05, vs adult age group in corresponding intervention. $P <0.05 vs isoprenaline in corresponding age group. N=6 per age group per drug treatment,
3. Discussion

3.1 Combined stimulation of PKA & Epac provides maximal protection against injury in the adult heart

The experiments described here show that PKA and Epac stimulation produces cardioprotection in the ex vivo perfused adult rat heart. Consistent with previous findings [17, 19], simultaneous stimulation of both parallel signalling pathways appears to be necessary for maximal cardioprotection in this model of ischaemia & reperfusion injury. Stimulation of either PKA or EPAC alone does not produce the same effect as with both; an intermediate response is seen. Our previous work [7, 23] demonstrated that β- adrenoceptor stimulation was in part responsible for a cardioprotective effect following a short period of activation. However, it is known that sustained activity at this receptor family does produce deleterious consequences for the heart at both the subcellular and whole organ level, including mitochondrial dysfunction, hypertrophy, heart failure, and death [24-26]. The potential for these untoward consequences of chronic receptor stimulation, as well as the unintended off-site consequences in the whole organism of receptor activation, mean that it is important that this work confirms prior findings of a receptor independent pathway to cAMP linked cardioprotection.

3.2 The immature perfused heart shows increased resistance to injury

These results in the immature heart also show the increased resistance of the developing heart to ischaemia & reperfusion injury. The developing heart does not display the same injury as that of the adult from a time-matched ischaemia/reperfusion injury; the duration of ischaemia needed to be extended from 30 to 50 min to obtain an injury which was comparable to that shown by the adult heart after a 30-min ischaemic stimulus. This is consistent with previous work showing a significant resistance to injury at this developmental stage, with an increase towards adulthood [18, 19, 23, 27]; this observation is thought due to developmental changes in cardiac energetics and mitochondrial function [28] and is correlated with clinical observations of changing vulnerability to injury in the developing heart widely recognised in the pediatric cardiac surgical community [29].

3.3 A combined action of PKA and Epac is needed to protect an immature heart against ischaemia/reperfusion

Once the injury was significant enough that a hypothetical cardioprotective effect could be observed, a significant reduction in infarct size and in biochemical markers of injury was seen with 8-Br perfusion. This effect was only convincingly seen with 8-Br; 6-Bnz did seem to produce a reduction in CK activity relative to control, but this effect was not matched with the change in infarct size; whilst CPT seemed to have no significant effect.

Thus, it seems as though in the immature heart activity of both PKA and EPAC is necessary for a protective effect just as in the adult. PKA activity alone has a small protective effect, and EPAC activity alone does not seem to produce protection. Only by simultaneous activation does the maximal protective effect become apparent, implying a synergistic mechanism of action.

PKA has long been linked to cardioprotection; suggested targets through which this is mediated are, for instance, significant phosphorylation of GSK-3β [30, 31], but also other molecular alterations less directly connected to the MPTP such as IKK/IKB and phosphodiesterases [32, 33]. Other mechanisms previously postulated also include an interaction with mitochondrial hexokinase II leading to MPTP inhibition [34].
The reasons and mechanisms by which Epac may have a cardioprotective effect, or may potentiate the effect due to the activity of PKA are less clear. Others have not found that CPT stimulation in similar models produces an isolated protective effect [17, 35]. It has been speculated that activation of PKCε, which is necessary for cardioprotection and known to be activated in Temperature Preconditioning as the archetype for this phenomenon, is a downstream consequence of Epac activity [8, 36].

The most obvious explanation of the marked protective effect of simultaneous activation of PKA and Epac may be that they have differing downstream effectors and so exhibit an additive effect. However, considering the extent of protection induced by the simultaneous activation of PKA and Epac compared to the much weaker effects of PKA and especially Epac alone, it is clear that the combined effect of PKA and Epac is not simply additive. It can be suggested that the transient Epac activation magnifies the protective effect of PKA either via enhancing activation of the pathways common to both enzymes or by activating other, yet unknown signalling pathways.

One of the possible common downstream targets of PKA and Epac could be PKCε. We have previously shown that the PKA inhibitor H-89 prevented PKC activation and cardioprotection induced by temperature preconditioning indicating that the latter activates PKC through PKA activation [8]. Also, our recent work has shown that PKCε (but not PKCδ) is involved in the strong cardioprotective effect of 8-Br [17]. Cazorla et al. have shown that Epac activates phospholipase C resulting in the production of diacylglycerol and inositol triphosphate, leading to PKC activation [37]. Others have found that the β-adrenoceptor/Epac/PLC pathway specifically activates PKCε [38]. PKA in turn can lead to PKC activation through increased ROS production [39] and by Ca^{2+}-dependent phospholipase C [40]. Consequently, activation of PKA and Epac may converge on PKCε in the cardioprotective effect induced by cAMP.

### 3.4 The Immature Heart’s Mitochondria are Less Susceptible to Ca^{2+}-Induced Swelling via the MPTP than the Adult Heart’s

These studies have shown that there is a measurable degree of swelling of the mitochondria in response to calcium in both adult and immature hearts. This degree of physiological sensitivity is demonstrably and significantly greater in the adult heart as compared to the immature; so whilst it is possible that this phenomenon may reflect unintended injury through the perfusion and isolation process, different groups exhibit this observation to differing degrees implying that there is a physiological basis to the age-dependent sensitivity of mitochondria to Ca^{2+} overload. It is possible that developmental changes in the proteome contribute to the observed differences, both in this physiological model and in the later I/R experiments. Further, the MPTP itself is even more poorly characterised in the immature heart in terms of its components and structure than in the adult; it may be that differences in these characteristics could account for the observed differences.

The overall physiological role of the MPTP in contexts aside from ischaemia and reperfusion injury remains unclear, and further studies on the MPTP in its intracellular environment is needed to address this.

### 3.5 Ischaemia & Reperfusion Injury Sensitises the MPTP to Ca^{2+} in both Immature and Adult Hearts

Both age groups demonstrated a significantly larger swelling response to calcium following exposure to I/R injury. The MPTP is well described as being sensitized to
opening stimuli during reperfusion, which is thought to be a consequence of the influence of reactive oxygen species. Therefore, these observations are expected in the context of prior work [41], but do confirm this work as a valid model of the known effects of reperfusion injury.

### 3.6 The MPTP is less likely to open in the Immature Heart exposed to Injury than the Adult Heart

Although the proportionate change in sensitivity to MPTP opening after I/R is greater in the immature control hearts, the absolute magnitude of this swelling response is less than a fifth that seen in the adult heart. A similar pattern is seen concerning mean rates of swelling. This is strikingly similar to the vulnerability pattern to whole heart global ischaemia and reperfusion injury, described as ‘bell-shaped’ or biphasic wherein vulnerability is thought to decrease from birth to 2 weeks post-natal age in the rat, before rising again to a peak at adulthood [19, 42]. It is therefore appealing to suggest that at least one of the factors underpinning this change in vulnerability, is changing behaviour of the MPTP with age [22]. Why the MPTP should change with age is not clear; the structure of this pore is still a matter of debate, and its constituents are still not comprehensively clear [43]. The structural knowledge that does exist is from work in adult tissues, and so cannot be assumed to remain consistent in the immature heart. It is further possible that mitochondrial morphology differs in the immature heart from that of the adult, which may have further consequences for the vulnerability to swelling.

### 3.7 MPTP inhibition is Replicated by cAMP Analogues but requires PKA & EPAC synergy

Prior perfusion of hearts with 8-Br reduces the sensitivity to swelling of both adult and immature mitochondria to almost, but not quite, the level seen with isoprenaline. This study was not powered or intended to be seen as a non-inferiority study between these two compounds. However, it may be that isoprenaline acting at the receptor level stimulates other occult pathways of signalling in parallel, or that there is a different amplitude of response along the downstream communication channels.

This study has however demonstrated that at a mitochondrial level, a cAMP analogue stimulating both PKA and Epac produces protection against ischaemia and reperfusion injury. This effect is not seen in either age group following stimulation with either CPT or 6-Bnz alone, where the response is not significantly different to that following I/R alone. This may imply that the reduction in sensitivity is due to a synergistic effect of the action of PKA and Epac. It is, however, also possible that the protection depends on a mechanism not stimulated by either of these agents but by an off-target effect of 8-Br.

### 4. Materials and Methods

#### 4.1 Extraction of hearts

In all cases, whole hearts were extracted from adult (c. 300g) and immature (14-day old) male Wistar rats. Animals were killed by cerebral concussion followed by cervical dislocation. A sternotomy incision was then made followed by reflection of the ribs, and the heart lifted out of the thorax. The aorta was cut along the descending portion, and the heart immediately placed in Krebs- Henseleit buffer chilled to 4C.

#### 4.2 Langendorff perfusion
The hearts were lifted onto a perfusion cannula (16G adult/ 24G immature) by the aorta, and fixed in place through a suture over the overlap of aorta and cannula. They were contained within an insulated glass jacket and maintained at normothermia.

A constant- flow perfusion methodology was used; Krebs-Henseleit (KH) buffer at 37°C was pumped through the apparatus at a rate of 10 ml/hr for adult hearts, and 4 ml/hr for immature hearts. The buffer was oxygenated with 95% O₂/5% CO₂. Additional reservoirs of KH buffer with the addition of the drug(s) under investigation were also included in the circuit; perfusion was switched to these reservoirs for the duration indicated in the experimental protocol.

4.3 Experimental Protocols

The experimental protocols for perfusion of hearts used for cAMP analogue perfusion, and corresponding controls, with CK activity and histological analysis is shown in Error! Reference source not found.. The control hearts in this group also had a 30 min equilibration period, followed by a 30 min period of global ischaemia, and subsequently a 120 min reperfusion period; intervention hearts were given a 5 min period of perfusion with a cAMP analogue. The agents chosen are selective agonists of either EPAC or PKA; or non-selective between these intermediaries (Known as 8-Br/ 6-Bnz/ CPT, (Described fully in Error! Reference source not found.). 10 µM CPT was used, with 5 µM 8-Br and 6-Bnz based upon prior work in our group demonstrating equipotency.

Figure 9 Graphical representations of the experimental protocols used for ex vivo heart perfusion in experiments measuring CK activity and area of infarct size. Data labels are the durations of each phase of the protocol.
Perfusion was followed by a 5 min washout period and then a 30 min period of ischaemia with a 120 min period of reperfusion (n=6 per age group per drug treatment + control). An additional group was added post-hoc of immature (P14; n=6 per drug treatment + control) hearts exposed to a 50 min duration of global ischaemia in order to match the degree of injury shown in adult hearts.

4.4 Measurement of Creatine Kinase Activity

Coronary effluent was collected from all of the perfused hearts and assayed for creatine kinase (CK) activity. Samples were collected prior to perfusion, and at 5- minute intervals following perfusion from hearts used for assessment of infarct size in order to obtain samples during the period of peak injury. Determination of CK activity was performed using a kit available from Randox (Crumlin, Northern Ireland). This assay uses the rate of formation of NADPH from NADP, dependent on ATP production catalyzed by CK, as a proxy for CK activity. The rate of absorbance change of the reaction mixture at 340 nm was measured which was then converted into an estimate of CK activity.

4.5 Measurement of Infarct Size

Following perfusion, each heart was stained with 1% triphenyl tetrazolium chloride (TTC) and fixed with 4% formaldehyde; this method results in infarcted areas appearing pale whilst viable tissue is stained a deep red colour. Each heart was sliced into 5 transverse sections, and each of those slices scanned on both sides to allow digital estimation of the area infarcted, expressed as a proportion of the size of that slice. The mean value across these sections was then taken as the area infarcted for that sample.

4.6 Perfusion protocols for mitochondrial isolation experiments

![Figure 10](image)

Figure 10  Experimental protocols for mitochondrial isolation experiments. Colours indicate phases of experiment; blue= standard perfusion with KH buffer; green= perfusion with KH containing a drug; red= normothermic global ischaemia.

Two sets of experiments were performed- shown in Figure 10. The first investigated the response of mitochondria isolated from hearts not exposed to I/R injury to isoprenaline, a non-selective β adrenoreceptor agonist (Adult control n= 6 intervention n=6, P14 control n=6, intervention n=6), whilst a second set of experiments examined the response...
following isoprenaline or PKA/Epac agonist and a 30- min global ischaemic injury followed by a 5 min reperfusion period. The cAMP analogues used in these experiments were as for the experiments for CK activity and infarct size and are shown in Error! Reference source not found..

| cAMP Analogue       | Function          | Perfusion Concentration |
|---------------------|-------------------|-------------------------|
| 6-Bnz-cAMP-AM (6-Bnz) | PKA activator     | 5 µM                    |
| 8-CPT-2′-O-Me-cAMP-AM (CPT) | Epac Activator | 10 µM                   |
| 8-Br-cAMP-AM (8-Br)  | Activator of both | 5 µM                    |

*Table 1 List of cAMP analogues used in our studies and in published work*

4.7 Mitochondrial Isolation

At the end of the perfusion protocols, the hearts were removed from the aortic cannula, and placed into chilled KH buffer. They were then homogenized using a Polytron Kinematica probe, and the resulting suspension centrifuged at 2000g for 90 seconds in order to separate the cell debris.

The supernatant from that step was then removed, and centrifuged again at 10,000g for two iterations of five min, with the supernatant removed and pellet resuspended each time. The resulting suspension was considered to be a preparation of isolated mitochondria.

These mitochondria would be of variable concentration due to the differing masses of the hearts used initially, and the varying proportion of mitochondria within those hearts. The concentration was then estimated through a Bradford essay, and this information used to normalise at 0.2 mg/ml in the mitochondrial swelling buffer.

4.8 Mitochondrial Swelling Assay

The swelling of these mitochondria in response to 1 mM Ca\(^{2+}\) was then assessed in a spectrophotometer (Evolution 201, ThermoScientific, Waltham, United States) at 520 nm. A baseline recording at 37 °C was made, before the addition of Ca\(^{2+}\) to the solution. The recording was then restarted and continued for at least 300 seconds or until any change in absorbance had ceased in order to measure the change in absorbance characteristics that accompanies swelling of the mitochondria as a consequence of MPTP opening triggered by the addition of Ca\(^{2+}\). The maximal change in absorbance amplitude was then calculated as a measure of effect size.
5. Conclusions

This work shows that the immature heart is innately more resistant to I/R injury than the adult in *ex vivo* perfusion models not only at the whole organ level, but also at the level of isolated organelles, inferring a role for the MPTP in the mechanism for that resistance. Adult and immature hearts show an inducible, similar, cardioprotection after activation of both PKA and EPAC; this persists despite the increased innate resistance of immature hearts to I/R injury. These data demonstrate the central role of the MPTP in cardioprotection, and suggest detailed study of its behaviour and broader mitochondrial function in the immature heart in order to further elucidate the mechanism of innate and inducible protection.

**Author Contributions:** Conceptualization, M.L, I.K. and M.S.S.; methodology, M.L, I.K., and M.S.S.; formal analysis, M.L and K.H.; investigation, M.L. and K.H.; resources, M.L. and M.S.S.; data curation, M.L. and K.H.; writing—original draft preparation, M.L.; writing—review and editing, M.L, I.K. and M.S.S.; supervision, M.S.S.; funding acquisition, M.L. and M.S.S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Medical Research Council (UK) grant number MR/N001389/1.

**Institutional Review Board Statement:** The study was conducted according to the laws of the Animals (Scientific Procedures) Act (1986) of the United Kingdom, and approved by the Animal Welfare Ethical Review Body of the University of Bristol (UIN/18/005, approved 19 April 2018).

**Data Availability Statement:** Data available on request from the corresponding author.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Depre C, Taegtmeyer H. Metabolic aspects of programmed cell survival and cell death in the heart. Cardiovascular research. 2000;45(3):538-48.
2. Eltzschig HK, Eckle T. Ischemia and reperfusion--from mechanism to translation. Nature medicine. 2011;17(11):1391-401.
3. Halestrap AP, Pasdois P. The role of the mitochondrial permeability transition pore in heart disease. Biochim Biophys Acta. 2009;1787(11):1402-15.
4. Honda HM, Korge P, Weiss JN. Mitochondria and ischemia/reperfusion injury. Ann N Y Acad Sci. 2005;1047:248-58.
5. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion—a target for cardioprotection. Cardiovascular research. 2004;61(3):372-85.
6. Lochner A, Genade S, Tromp E, Podzuweit T, Moolman JA. Ischemic preconditioning and the beta-adrenergic signal transduction pathway. Circulation. 1999;100(9):958-66.
7. Khaliulin I, Halestrap AP, Bryant SM, Dudley DJ, James AF, Suleiman MS. Clinically-relevant consecutive treatment with isoproterenol and adenosine protects the failing heart against ischaemia and reperfusion. Journal of translational medicine. 2014;12:139.
8. Khaliulin I, Parker JE, Halestrap AP. Consecutive pharmacological activation of PKA and PKC mimics the potent cardioprotection of temperature preconditioning. Cardiovascular research. 2010;88(2):324-33.
9. Cannavo A, Liccardo D, Koch WJ. Targeting cardiac β-adrenergic signaling via GRK2 inhibition for heart failure therapy. Front Physiol. 2013;4:264.
10. Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res. 2013;113(6):739-53.
11. Bers DM. Going to cAMP just got more complicated. J Physiol. 2007;583(Pt 2):415-6.
12. de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, et al. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature. 1998;396(6710):474-7.
13. Okumura S, Fujita T, Cai W, Jin M, Namekata I, Mototani Y, et al. Epac1-dependent phospholamban phosphorylation mediates the cardiac response to stresses. The Journal of clinical investigation. 2014;124(6):283-91.
14. Pereira L, Ruiz-Hurtado G, Morel E, Laurent AC, Metrich M, Dominguez-Rodriguez A, et al. Epac enhances excitation-transcription coupling in cardiac myocytes. Journal of molecular and cellular cardiology. 2012;52(1):283-91.
15. Dudley DJ, Suleiman MS, Bond M, James AF, Khaliulin I. 10 Cell-Permeable Cyclic AMP as a Novel Cardioprotective Agent. Heart (British Cardiac Society). 2014;100(Suppl 1):A4.
16. Khaliulin I, Ascione R, Maslov LN, Amal H, Suleiman MS. Preconditioning or Postconditioning with 8-Br-cAMP-AM Protects the Heart against Regional Ischemia and Reperfusion: A Role for Mitochondrial Permeability Transition. Cells. 2021;10(5).
17. Khaliulin I, Bond M, James AF, Dyar Z, Amini R, Johnson JL, et al. Functional and cardioprotective effects of simultaneous and individual activation of protein kinase A and Epac. Br J Pharmacol. 2017;174(6):438-53.
18. Ostadal B, Ostadalova I, Kolar F, Sedmera D. Developmental determinants of cardiac sensitivity to hypoxia. Can J Physiol Pharmacol. 2014;92(7):566-74.
19. Ostadalova I, Ostadal B, Kolar F, Parratt JR, Wilson S. Tolerance to ischaemia and ischaemic preconditioning in neonatal rat heart. Journal of molecular and cellular cardiology. 1998;30(4):857-65.
20. Vetter R, Studer R, Reinecke H, Kolar F, Ostadalova I, Drexler H. Reciprocal changes in the postnatal expression of the sarcolemmal Na+-Ca(2+)-exchanger and SERCA2 in rat heart. Journal of molecular and cellular cardiology. 1995;27(8):1689-701.
21. Studer R, Reinecke H, Vetter R, Holtz J, Drexler H. Expression and function of the cardiac Na+/Ca2+ exchanger in postnatal development of the rat, in experimental-induced cardiac hypertrophy and in the failing human heart. Basic research in cardiology. 1997;92 Suppl 1:53-8.
22. Balaska D, Halestrap A, Suleiman S, Griffiths E. Increased susceptibility to pore-opening in heart mitochondria from neonatal compared with adult rats. J Physiol. 2005.
23. Lewis M, Szobi A, Balaska D, Khaliulin I, Adameova A, Griffiths E, et al. Consecutive Isoproterenol and Adenosine Treatment Confers Marked Protection against Reperfusion Injury in Adult but Not in Immature Heart: A Role for Glycogen. Int J Mol Sci. 2018;19(2).
24. Dorn GW, 2nd, Tepe NM, Wu G, Yatani A, Liggett SB. Mechanisms of impaired beta-adrenergic receptor signaling in G( alpha q)-mediated cardiac hypertrophy and ventricular dysfunction. Mol Pharmacol. 2000;57(2):278-87.
25. Appukuttan A, Kasseckert SA, Micoogullari M, Flacke JP, Kumar S, Woste A, et al. Type 10 adenylyl cyclase mediates mitochondrial Bax translocation and apoptosis of adult rat cardiomyocytes under simulated ischaemia/reperfusion. Cardiovascular research. 2012;93(2):340-9.
26. Rau CD, Wang J, Avetisyan R, Romay MC, Martin L, Ren S, et al. Mapping genetic contributions to cardiac pathology induced by Beta-adrenergic stimulation in mice. Circ Cardiovasc Genet. 2015;8(1):40-9.
27. Ostadal B, Ostadalova I, Kolar F, Charvatova Z, Netuka I. Ontogenetic development of cardiac tolerance to oxygen deprivation - possible mechanisms. Physiol Res. 2009;58 Suppl 2:S1-12.
28. Modi P, Suleiman MS. Myocardial taurine, development and vulnerability to ischemia. Amino acids. 2004;26(1):65-70.
29. Imura H, Caputo M, Parry A, Pawade A, Angelini GD, Suleiman MS. Age-dependent and hypoxia-related differences in myocardial protection during pediatric open heart surgery. Circulation. 2001;103(11):1551-6.
30. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. The Journal of clinical investigation. 2004;113(11):1535-49.
31. Gomez L, Paillard M, Thibault H, Derumeaux G, Ovize M. Inhibition of GSK3beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation. 2008;117(21):2761-8.
32. Omori K, Kota J. Overview of PDEs and their regulation. Circ Res. 2007;100(3):309-27.
33. Zhang Y, Wang XL, Zhao J, Wang YJ, Lau WB, Yuan YX, et al. Adiponectin inhibits oxidative/nitrative stress during myocardial ischemia and reperfusion via PKA signaling. Am J Physiol Endocrinol Metab. 2013;305(12):E1436-43.
34. Pasdois P, Parker JE, Halestrap AP. Extent of mitochondrial hexokinase II dissociation during ischemia correlates with mitochondrial cytochrome c release, reactive oxygen species production, and infarct size on reperfusion. J Am Heart Assoc. 2012;2(1):e005645.
35. Duquesnes N, Derangeon M, Métrich M, Lucas A, Mateo P, Li L, et al. Epac stimulation induces rapid increases in connexin43 phosphorylation and function without preconditioning effect. Pflügers Archiv - European Journal of Physiology. 2010;460(4):731-41.
36. Khaliliulin I, Clarke SJ, Lin H, Parker J, Suleiman MS, Halestrap AP. Temperature preconditioning of isolated rat hearts—a potent cardioprotective mechanism involving a reduction in oxidative stress and inhibition of the mitochondrial permeability transition pore. J Physiol. 2007;581(Pt 3):1147-61.
37. Cazorla O, Lucas A, Poirier F, Lacampagne A, Lezoualc'h F. The cAMP binding protein Epac regulates cardiac myofilament function. Proceedings of the National Academy of Sciences. 2009;106(33):14144-9.
38. Li L, Cai H, Liu H, Guo T. β-adrenergic stimulation activates protein kinase Cε and induces extracellular signal-regulated kinase phosphorylation and cardiomyocyte hypertrophy. Mol Med Rep. 2015;11(6):4373-80.
39. Novalija E, Kevin LG, Camara AK, Bosnjak ZJ, Kampine JP, Stowe DF. Reactive oxygen species precede the epsilon isoform of protein kinase C in the anesthetic preconditioning signaling cascade. Anesthesiology. 2003;99(2):421-8.
40. Dekker LR, Coronel R, VanBavel E, Spaan JA, Opthof T. Intracellular Ca2+ and delay of ischemia-induced electrical uncoupling in preconditioned rabbit ventricular myocardium. Cardiovascular research. 1999;44(1):101-12.
41. Suleiman MS, Halestrap AP, Griffiths EJ. Mitochondria: a target for myocardial protection. Pharmacology & therapeutics. 2001;89(1):29-46.
42. Riva E, Hearse DJ. Age-dependent changes in myocardial susceptibility to ischemic injury. Cardioscience. 1993;4(2):85-92.
43. Ong SB, Samangouei P, Kalkhoran SB, Hausenloy DJ. The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury. Journal of molecular and cellular cardiology. 2015;78:23-34.